AbbVie vs. Merck: Which Pharma Stock Offers Better Value?
AbbVie Inc. (NYSE:ABBV) and Merck & Co., Inc. (NYSE:MRK) have something important in common that is important for investors, ...
Model output · Signal date 2026-10-16
Abbvie Inc. (ABBV) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Rating · 90D
Alpha
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
Middle 30%
of 5171 stocks scored
Rank correlation · 90D
1.0%
Spearman, 357 dates
Market Cap
$504.46B
mega-cap · #3 of 60 peers
Summary
Abbvie Inc. (ABBV) stock forecast summary
On Oct. 16, 2026, ABBV is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5171 stocks scored that day.
Abbvie Inc. is a mega-cap company with a market capitalization of $504.46B. It ranks number 3 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For ABBV, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 1.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 1.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ABBV included.
Follow ABBV freePrice
ABBV price chart and AI forecast
Cross-section · 2026-10-16
How ABBV ranks among 5171 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Abbvie Inc. (ABBV) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | ABBV | Rank |
|---|---|---|
| Market Cap | $504.46B | 3/60 |
| P/E Ratio | 73.76x | 7/32 |
| Dividend Yield | 2.37% | 4/10 |
| EPS | $3.87 | – |
| Revenue/Share | $36.44 | – |
| FCF/Share | $10.30 | – |
Profitability & Margins
| Metric | ABBV | Rank |
|---|---|---|
| ROA | 4.7% | 19/43 |
| ROIC | 18.1% | 9/46 |
| Gross Margin | 71.5% | 25/35 |
| Operating Margin | 26.2% | 10/39 |
| Net Margin | 9.8% | 16/35 |
| EBT Margin | 13.5% | 21/46 |
| Tax Rate | 27.4% | – |
Financial Health
| Metric | ABBV | Rank |
|---|---|---|
| Current Ratio | 0.81x | 58/59 |
| Quick Ratio | 0.69x | 38/43 |
| Interest Coverage | 8.6x | 11/36 |
| Working Capital | -$7.97B | 59/59 |
Cash Flow
| Metric | ABBV | Rank |
|---|---|---|
| Operating Cash Flow | $19.51B | 10/59 |
| Free Cash Flow | $18.21B | 7/50 |
| Capital Spending | -$1.30B | 40/50 |
| OCF Growth YoY | 1.2% | 20/33 |
| FCF Growth YoY | -0.2% | 23/31 |
| FCF/Sales | 28.3% | 8/42 |
| CapEx/Sales | 2.0% | 26/42 |
Operational Efficiency
| Metric | ABBV | Rank |
|---|---|---|
| Asset Turnover | 0.48x | 22/40 |
| Receivables Turnover | 4.7x | 24/37 |
| Inventory Turnover | 3.6x | 9/35 |
| Fixed Assets Turnover | 11.1x | 15/41 |
| Days Sales Outstanding | 78 days | 13/37 |
| Days Inventory | 102 days | 27/35 |
| Payables Period | 662 days | 2/25 |
| Cash Conversion Cycle | -482 days | 23/23 |
Income Statement
| Metric | ABBV | Rank |
|---|---|---|
| Total Revenue | $64.39B | 8/46 |
| Operating Income | $16.87B | 6/51 |
| Net Income | $6.31B | 7/46 |
| R&D Expense | $9.71B | 11/58 |
| SG&A Expense | $14.67B | 6/40 |
| Cost of Goods Sold | $18.36B | 9/36 |
Dividend & Shareholder Information
| Metric | ABBV | Rank |
|---|---|---|
| Dividends Per Share | $6.78 | – |
| Payout Ratio | 175.2% | 3/10 |
| Shares Outstanding | 1767M | – |
| Net Income Growth | 67.7% | 5/18 |
| EPS Growth | 80.8% | 6/24 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $33.67B | 24.9% of assets |
| Cash & Short-term Investments | $6.57B | 4.9% of assets |
| Accounts Receivable | $13.82B | 10.2% of assets |
| Inventory | $5.13B | 3.8% of assets |
| Total Liabilities | $141.00B | |
| Short-term Debt | $8.34B | 6.2% of assets |
Quarterly Financial Reports
ABBV quarterly financials and insider trading
Industry Peers · Pharmaceutical Preparations
Abbvie Inc. (ABBV) industry peers
Companies classified under the same SEC industry code as Abbvie Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| ABBV Abbvie Inc. | ▶ | $504.46B |
| LLY Eli Lilly & Co | ▶ | $1.18T |
| JNJ Johnson & Johnson | ▼ | $610.38B |
| MRK Merck & Co., Inc. | ▲ | $358.21B |
| NVS Novartis Ag | ▼ | $286.95B |
| AZN Astrazeneca Plc | ▼ | $256.39B |
| ABT Abbott Laboratories | ▼ | $182.37B |
| NVO Novo Nordisk A S | ▼ | $174.29B |
| PFE Pfizer Inc | ▶ | $167.80B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▶ | $128.95B |
| BMY Bristol Myers Squibb Co | ▶ | $122.05B |
| GSK Gsk Plc | ▼ | $100.46B |
| SNY Sanofi | ▼ | $99.33B |
| REGN Regeneron Pharmaceuticals, Inc. | ▶ | $82.34B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $60.76B |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $47.91B |
| ONC Beone Medicines Ltd. | ▲ | $42.53B |
| ZTS Zoetis Inc. | ▼ | $32.40B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▶ | $31.02B |
| RPRX Royalty Pharma Plc | ▶ | $26.29B |
| ROIV Roivant Sciences Ltd. | ▲ | $24.59B |
| GMAB Genmab A/S | ▲ | $23.80B |
| UTHR United Therapeutics Corp | ▶ | $23.23B |
| INSM Insmed Inc | ▶ | $21.67B |
| VTRS Viatris Inc | ▼ | $20.93B |
| ASND Ascendis Pharma A/S | ▲ | $14.85B |
| JAZZ Jazz Pharmaceuticals Plc | ▼ | $13.92B |
| BBIO Bridgebio Pharma, Inc. | ▶ | $12.98B |
| SMMT Summit Therapeutics Inc. | ▶ | $12.26B |
| CORT Corcept Therapeutics Inc | ▲ | $11.91B |
| ELAN Elanco Animal Health Inc | ▼ | $11.77B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.77B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.62B |
| BMRN Biomarin Pharmaceutical Inc | ▶ | $10.58B |
| TGTX Tg Therapeutics, Inc. | ▲ | $8.89B |
| PTGX Protagonist Therapeutics, Inc | ▶ | $8.84B |
| CYTK Cytokinetics Inc | ▲ | $8.61B |
| AXSM Axsome Therapeutics, Inc. | ▲ | $8.23B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $7.90B |
| ABVX Abivax S.A. | ▼ | $7.74B |
| IONS Ionis Pharmaceuticals Inc | ▲ | $7.33B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.06B |
| PRAX Praxis Precision Medicines, Inc. | ▲ | $6.93B |
| ALKS Alkermes Plc. | ▲ | $6.92B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▼ | $6.24B |
| AMRX Amneal Pharmaceuticals, Inc. | ▲ | $6.13B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▲ | $6.06B |
| LGND Ligand Pharmaceuticals Inc | ▶ | $5.95B |
| BLTE Belite Bio, Inc | ▲ | $5.62B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.35B |
| COGT Cogent Biosciences, Inc. | ▶ | $5.12B |
| PTCT Ptc Therapeutics, Inc. | ▲ | $5.09B |
| ORKA Oruka Therapeutics, Inc. | ▲ | $4.89B |
| MANE Veradermics, Inc | ▲ | $4.81B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.72B |
| ERAS Erasca, Inc. | ▲ | $4.68B |
| EWTX Edgewise Therapeutics, Inc. | ▲ | $4.04B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.03B |
| INDV Indivior Pharmaceuticals, Inc. | ▶ | $3.97B |
| TNGX Tango Therapeutics, Inc. | ▲ | $3.83B |
Where ABBV sits on the market map
Life Sciences · Pharmaceutical Preparations
News
Abbvie Inc. (ABBV) stock news
Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment?
Pfizer Inc. (NYSE:PFE) trades at a considerable discount to AbbVie Inc. (NYSE:ABBV), despite both companies reporting growth ...
AbbVie Inc. (ABBV) is attracting investor attention: Here is what you should know
AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...
FAQ
Abbvie Inc. (ABBV) stock forecast FAQ
What is the Abbvie Inc. (ABBV) stock forecast?
On Oct. 16, 2026, ABBV is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5171 stocks scored that day.
How accurate are Abbvie Inc. stock predictions?
For ABBV, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 1.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 1.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Abbvie Inc. forecasts updated?
Abbvie Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Abbvie Inc.'s industry peers?
60 issuers in our coverage, ABBV included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN), Abbott Laboratories (ABT).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.